All Stories

  1. Altered MCM Protein Levels and Autophagic Flux in Aged and Systemic Sclerosis Dermal Fibroblasts
  2. Acute retinal artery occlusion in systemic sclerosis: A rare manifestation of systemic sclerosis fibroproliferative vasculopathy
  3. Role of Endothelial to Mesenchymal Transition in the Pathogenesis of the Vascular Alterations in Systemic Sclerosis
  4. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of Systemic Sclerosis and Sjögren's Syndrome
  5. Strategies for anti-fibrotic therapies
  6. Caveolin-1 Deficiency Induces Spontaneous Endothelial-to-Mesenchymal Transition in Murine Pulmonary Endothelial Cells in Vitro
  7. Collagen Content in Skin and Internal Organs of the Tight Skin Mouse: An Animal Model of Scleroderma
  8. Role of Oxidative Stress and Reactive Oxygen Radicals in the Pathogenesis of Systemic Sclerosis
  9. Effects of Scleroderma Antibodies and Pooled Human Immunoglobulin on Anal Sphincter and Colonic Smooth Muscle Function
  10. Systemic sclerosis disease modification clinical trials design: Quo vadis?
  11. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts
  12. Severe Eosinophilic Syndrome Associated with the Use of Probiotic Supplements: A New Entity?
  13. Predictors of early mortality in systemic sclerosis: a case–control study comparing early versus late mortality in systemic sclerosis
  14. Nephrogenic Systemic Fibrosis
  15. Effect of Protein Kinase C delta (PKC-δ) Inhibition on the Transcriptome of Normal and Systemic Sclerosis Human Dermal Fibroblasts In Vitro
  16. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
  17. Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders
  18. Scleroderma Renal Crisis-Like Acute Renal Failure Associated With Mucopolysaccharide Accumulation in Renal Vessels in a Patient With Scleromyxedema
  19. Protein kinase Cδ and c‐Abl kinase are required for transforming growth factor β induction of endothelial–mesenchymal transition in vitro
  20. 46, XXSRY-Positive Male Syndrome Presenting with Primary Hypogonadism in the Setting of Scleroderma
  21. Role of Growth Factors in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis
  22. Proteomic Analysis Identification of a Pattern of Shared Alterations in the Secretome of Dermal Fibroblasts from Systemic Sclerosis and Nephrogenic Systemic Fibrosis
  23. Maternal Mixed Connective Tissue Disease and Offspring with Chondrodysplasia Punctata
  24. Biomarkers in systemic sclerosis
  25. Mechanism of NSF: New evidence challenging the prevailing theory
  26. Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics
  27. S1244 Immunoglobulins (IgGs) from Systemic Sclerosis (SSC) Patients Attenuate M3 Muscarinic Receptor Activation in Rat Internal Anal Sphincter (IAS) Smooth Muscle Cells (SMC)
  28. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents
  29. Caveolin-1−/− Null Mammary Stromal Fibroblasts Share Characteristics with Human Breast Cancer-Associated Fibroblasts
  30. Caveolin-1, transforming growth factor-β receptor internalization, and the pathogenesis of systemic sclerosis
  31. Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis
  32. Molecular ablation of transforming growth factor β signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosis
  33. Targeting NF-κB: A Promising Molecular Therapy in Inflammatory Arthritis
  34. T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro
  35. Significance of Ground-glass Opacity on HRCT in Long-term Follow-up of Patients With Systemic Sclerosis
  36. Regulation of the human SOX9 promoter by Sp1 and CREB
  37. Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy: Clinical Aspects
  38. The role of allograft inflammatory factor 1 in systemic sclerosis
  39. Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor β
  40. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin
  41. Acute myocardial infarction in systemic sclerosis patients: a case series
  42. Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the Literature
  43. Statins and the vasculopathy of systemic sclerosis: Potential therapeutic agents?
  44. Single amino acid substitutions in the C-terminus of collagen II alter its affinity for collagen IX
  45. Scleroderma Fibroblast Survival in Aktion
  46. Microchimerism and systemic sclerosis
  47. A Role for the Androgen Receptor in Collagen Content of the Skin
  48. Position of single amino acid substitutions in the collagen triple helix determines their effect on structure of collagen fibrils
  49. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches
  50. Involvement of skeletal muscle in dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy)
  51. Impaired Rectoanal Inhibitory Response in Scleroderma (Systemic Sclerosis): An Association with Fecal Incontinence
  52. B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts
  53. Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis
  54. Primary B-cell lymphoma of the tongue in a patient with systemic sclerosis
  55. Spontaneous Rat Model of Alopecia Areata in the Dundee Experimental Bald Rat (DEBR)
  56. Skeletal dysplasias and the osteoarthritic phenotype
  57. Pulmonary and Activation-Regulated Chemokine Stimulates Collagen Production in Lung Fibroblasts
  58. Systemic sclerosis: current views of its pathogenesis
  59. Transcriptional activation of α1(III) procollagen gene in Tsk2/+ dermal fibroblasts
  60. Murine animal models of systemic sclerosis
  61. Increased Microchimeric CD4+ T Lymphocytes in Peripheral Blood from Women with Systemic Sclerosis
  62. Modulation of transcriptional activity of collagen genes for the treatment of fibrotic diseases
  63. Increased life span of human osteoarthritic chondrocytes by exogenous expression of telomerase
  64. Hepatitis C Virus Infection, Inflammatory Myopathy, and Pulmonary Fibrosis: Are They Related?
  65. Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors
  66. Collagen II Containing a Cys Substitution for Arg-α1−519:  Abnormal Interactions of the Mutated Molecules with Collagen IX
  67. Role of protein kinase C-δ in the regulation of collagen gene expression in scleroderma fibroblasts
  68. Role of protein kinase C-δ in the regulation of collagen gene expression in scleroderma fibroblasts
  69. Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride
  70. CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: Demonstration of increased binding in systemic sclerosis fibroblasts
  71. Evaluation of anorectal function in scleroderma
  72. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I
  73. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I
  74. Alterations in the regulation of expression of the ?1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma)
  75. Alterations in the regulation of expression of the αl(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma)
  76. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA–Cw antigens
  77. New perspectives on the etiology of systemic sclerosis
  78. Transcriptional activation of the α1(I) procollagen gene and up‐regulation of α1(I) and α1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice
  79. The mouse tight skin ( Tsk ) phenotype is not dependent on the presence of mature T and B lymphocytes
  80. Identification of elements in the promoter region of the α1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis
  81. Modulation of basal expression of the human α1(I) procollagen gene (COL1A1) by tandem NF-1/Sp1 promoter elements in normal human dermal fibroblasts
  82. Modulation of human α1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro
  83. Identification of Fetal DNA and Cells in Skin Lesions from Women with Systemic Sclerosis
  84. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo‐controlled, double‐blind study
  85. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study
  86. Effects of interferon‐γ and tumor necrosis factor α on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes
  87. Effects of interferon-? and tumor necrosis factor ? on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes
  88. Characterization of human chondrocyte and fibroblast type XII collagen cDNAs
  89. T Cells Infiltrating the Skin ofTsk2Scleroderma-Like Mice Exhibit T Cell Receptor Bias
  90. Characterization of human type II procollagen and collagen-specific antibodies and their application to the study of human type II collagen processing and ultrastructure
  91. Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms
  92. Increased activity of the α1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome
  93. PATHOGENESIS OF SCLERODERMA
  94. Transcriptional activation of the α1(1) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences
  95. Alteration in the conformational stability of collagen caused by the incorporation of the lysine analogue S-2-aminoethylcysteine
  96. Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis
  97. Transplantation of Systemic Sclerosis (SSc) Skin Grafts into Severe Combined Immunodef icient Mice: Increased Presence of SSc Leukocytes in SSc Skin Grafts and Autoantibody Production following Autologous Leukocyte Transfer
  98. The tight skin 2 mouse
  99. Positive regulation of human α1 (I) collagen promoter activity by transcription factor Sp1
  100. Autoantibodies in Sera from Patients with L-Tryptophan-Associated Eosinophilia-Myalgia Syndrome
  101. Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis
  102. Familial Hydroxyapatite Chondrocalcinosis with Spondyloepiphyseal Dysplasia
  103. Animal Models of Scleroderma: Contrasts and Comparisons
  104. Retroviruses and the Pathogenesis of Systemic Sclerosis
  105. Mononuciear Cellular Infiltrates in Clinically Involved Skin from Patients with Systemic Sclerosis of Recent Onset Predominantly Consist of Monocytes/Macrophages
  106. Amplification and characterization of type XII collagen cDNAs from human fetal chondrocytes and fibroblasts
  107. Genetic linkage analyses of the fibrillin genes, Fbn1 and Fbn2, in the mouse genome
  108. Modulation of extracellular matrix (ECM) gene expression by heparin, endothelial cell growth factor (ECGF), and acidic and basic fibroblast growth factors (EGFs) in human dermal microvascular endothelial cells (HDMVEC)
  109. Identification of a mutation in the type X collagen gene (COL10A1) in a family with Schmid metaphyseal chondrodysplasia
  110. Formation of nodular structures resembling mature articular cartilage in long–term primary cultures of human fetal epiphyseal chondrocytes on a hydrogel substrate
  111. Animal models of systemic sclerosis
  112. Familial spondyloepiphyseal dysplasia tarda, brachydactyly, and precocious osteoarthritis associated with an arginine 75 → cysteine mutation in the procollagen type ii gene in a kindred of chiloe islanders.
  113. In vitro Cytokine Modulation of Intercellular Adhesion Molecule-1 Expression on Systemic Sclerosis Dermal Fibroblasts
  114. Identification of a mutation in type X collagen in a family with Schmid metaphyseal chondrodysplasia
  115. Effects of calcium deficiency on chondrocyte hypertrophy and type X collagen expression in chick embryonic sternum
  116. Spondyloepiphyseal dysplasia and precocious osteoarthritis in a family with an Arg75?Cys mutation in the procollagen type II gene (COL2A1)
  117. Glycosaminoglycans and Chondroitin/Dermatan Sulfate Proteoglycans in the Myocardium of a Non-Human Primate
  118. The Tight Skin (Tsk) Mutation in the Mouse, a Model for Human Fibrotic Diseases, Is Tightly Linked to the β2-Microglobulin (B2m) Gene on Chromosome 2
  119. Regulation of α1 (I) collagen gene promoter by tumor necrosis factor-α in human dermal fibroblasts
  120. Amplification of cDNAs for Human Cartilage-Specific Types II, IX and XI Collagens from Chondrocytes and Epstein-Barr Virus-Transformed Lymphocytes
  121. Exclusion of type II and type VI procollagen gene mutations in a five‐generation family with multiple epiphyseal dysplasia
  122. Immunopathogenesis of Systemic Sclerosis: Possible Role of Retroviruses
  123. L-Tryptophan and the Eosinophilia-Myalgia Syndrome: Current Understanding of the Etiology and Pathogenesis
  124. L-Tryptophan and the Eosinophilia-Myalgia Syndrome: Current Understanding of the Etiology and Pathogenesis.
  125. In situ Expression of Cytokines and Cellular Adhesion Molecules in the Skin of Patients with Systemic Sclerosis
  126. Reply
  127. The Cause and Pathogenesis of the Eosinophilia-Myalgia Syndrome
  128. Treatment of systemic sclerosis with recombinant interferon‐γ. A phase I/II clinical trial
  129. Polymerase chain reaction — amplification of the coding sequence of the type X collagen gene from genomic DNA and identification of a polymorphism that changes GLY to ARG at position 545 by single-strand conformation polymorphism analysis
  130. EOSINOPHILIA‐MYALGIA SYNDROME
  131. Elevated expression of β1 and β2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset
  132. Autoantibodies to Nuclear Lamin C in the Eosinophilia—Myalgia Syndrome Associated with L‐Tryptophan Ingestion
  133. The eosinophilia-myalgia syndrome and eosinophilic fasciitis
  134. Evidence for autoimmunity in the tight skin mouse model of systemic sclerosis
  135. Comparison of morphological and biochemical characteristics of cultured chondrocytes isolated from proliferative and hypertrophic zones of bovine growth plate cartilage
  136. Structure of cDNAs Encoding the Triple-Helical Domain of Murine α2 (VI) Collagen Chain and Comparison to Human and Chick Homologues. Use of Polymerase Chain Reaction and Partially Degenerate Oligonucleotides for Generation of Novel cDNA Clones
  137. Elevated Expression of the Genes for Transforming Growth Factor-β1 and Type VI Collagen in Diffuse Fasciitis Associated with the Eosinophilia-Myalgia Syndrome
  138. The eosinophilia-myalgia syndrome and eosinophilic fasciitis
  139. Increased expression of type VI collagen genes in systemic sclerosis
  140. Transforming Growth Factor‐β Stimulates the Expression of Prostaglandin Synthase in Normal Human Fibroblastsa
  141. Interferon‐γ Modulates the Effect of Transforming Growth Factor‐β on Extracellular Matrix Gene Expression by Fibroblastsa
  142. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome
  143. Evaluation of Transforming Growth Factor β and Type I Procollagen Gene Expression in Fibrotic Skin Disease by In Situ Hybridization
  144. Genetic Linkage of a Polymorphism in the Type II Procollagen Gene (COL2A1) to Primary Osteoarthritis Associated with Mild Chondrodysplasia
  145. Articular Cartilage Preservation and Storage
  146. Other fibrosing syndromes
  147. The Tight Skin (TSK) Mouse
  148. Progressive systemic sclerosis: Mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients
  149. PGE2 causes a coordinate decrease in the steady state levels of fibronectin and types I and III procollagen mRNAs in normal human dermal fibroblasts
  150. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma
  151. Regulation of fibroblast proliferation and collagen synthesis by cytokines
  152. Development of severe limited scleroderma in complicated Raynaud's phenomenon after limb immobilization: Report of two cases and study of collagen biosynthesis
  153. Penicillamine-Induced Rapidly Progressive Glomerulonephritis in Patients With Progressive Systemic Sclerosis: Successful Treatment of Two Patients and a Review of the Literature
  154. Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-β
  155. Inhibition of excessive scleroderma fibroblast collagen production by recombinant γ‐interferon: Association with a coordinate decrease in types I and III procollagen messenger RNA levels
  156. Expression of Type X collagen mRNA levels in embryonic chick sternum during development
  157. Development of Rheumatoid Factors and Anti-F(ab′)<sub>2</sub> Antibodies in Guinea Pigs Immunized with Type II Bovine Collagen
  158. Transcriptional Control of Human Diploid Fibroblast Collagen Synthesis by γ‐Interferona
  159. Selective inhibition of excessive scleroderma fibroblast collagen production by lymphokines from normal human mononuclear cells
  160. Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture
  161. Transcriptional control of human diploid fibroblast collagen synthesis by γ-interferon
  162. Scleroderma‐like alterations in collagen metabolism occurring in the TSK (tight skin) mouse
  163. Sequential changes in the mechanical properties of viable articular cartilage stored in vitro
  164. Characterization of a lymphokine produced by human T cells which inhibits collagen synthesis
  165. Cellular immune dysfunction and the pathogenesis of scleroderma
  166. Biosynthesis of a Low Molecular Weight Collagen by Rabbit Growth Plate Cartilage Organ Cultures
  167. Biochemical Characterization of Collagens and of a Non-Collagenous Protein Synthesized by Guinea Pig Lung Fibroblasts in Culture
  168. Immune modulation of connective tissue functions: Studies on the production of collagen synthesis inhibitory factor by populations of human peripheral blood mononuclear cells
  169. MONOCYTE AND LYMPHOCYTE PRODUCTS CAN INHIBIT COLLAGEN SYNTHESIS BY HUMAN SKIN FIBROBLASTS IN CULTURE
  170. Inhibition of proteoglycan degradation in rabbit articular cartilage organ cultures by superoxide dismutase and proteolytic enzyme inhibitors
  171. Effect of various aminoacid analogues on chick tendon procollagen synthesis and secretion: Selective inhibition by S-2-aminoethyl cysteine
  172. Isolation and partial characterization of proteoglycans from sheep lung parenchyma
  173. Articular cartilage preservation and storage
  174. Synovitis in secondary syphilis
  175. Identification of two new collagen α-chains in extracts of lathyritic chick embryo tendons
  176. Identification of collagen α1(I) trimer in embryonic chick tendons and calvaria
  177. Increased sensitivity of scleroderma fibroblasts in culture to stimulation of protein and collagen synthesis by serum
  178. Collagen synthesis by scleroderma fibroblasts in culture
  179. Effects of trypsin on the platelet-aggregating activity of mouse tumor cells
  180. Simultaneous aggregation and release from platelets monitored continuously in plasma
  181. Secretion of unhydroxylated chick tendon procollagen
  182. Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid
  183. Decreased thermal stability of collagens containing analogs of proline or lysine
  184. Hydroxyproline content determines the denaturation temperature of chick tendon collagen
  185. Hydroxyproline stabilizes the triple helix of chick tendon collagen
  186. Characterization of the precursor forms of the α1 and α2 chains of collagen from matrix-free tendon cells
  187. Further evidence for a transport form of collagen. Its extrusion and extracellular conversion to tropocollagen in embryonic tendon
  188. Collagens
  189. Systemic Sclerosis